[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351866-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351866-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","regional-variations-in-guideline-concordance-for-women-with-triple-negative-and-her2-breast-cancer-in-nova-scotia","Regional Variations in Guideline Concordance for Women with Triple-Negative and HER2+ Breast Cancer in Nova Scotia","","Systematic neoadjuvant therapy (NAT) is recommended for non-metastatic triple-negative (TNBC) and HER2+ breast cancer with tumor size ≥2 cm. This retrospective study quantified the proportion of eligible Nova Scotia patients receiving guideline-concordant NAT and tested differences by administrative zone. Using Nova Scotia Breast Screening Program data (2021–2023), 67.0% of 291 theoretically eligible women received NAT. Receipt varied significantly by zone (Central 73.1%, Eastern 72.9%, Northern 57.4%, Western 54.2%, p=0.030). Findings reveal regional disparities and support targeted improvement strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/regional-variations-in-guideline-concordance-for-women-with-triple-negative-and-her2-breast-cancer-in-nova-scotia/351866/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/regional-variations-in-guideline-concordance-for-women-with-triple-negative-and-her2-breast-cancer-in-nova-scotia/351866.png","ImageObject",300,407,{"name":42,"@type":43},"4398046744996","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What treatment does the study focus on for eligible patients?","Question",{"text":63,"@type":64},"The study focuses on guideline-concordant neoadjuvant systemic therapy (NAT) for non-metastatic TNBC and HER2+ breast cancers with diagnosis tumor size ≥2 cm.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was eligibility for NAT determined in the analysis?",{"text":68,"@type":64},"Eligibility was based on a defined wait time of ≥4 months between core biopsy and surgery, for adult patients (18–80 years) with incident non-metastatic ≥T2 breast cancer between 2021 and 2023.",{"name":70,"@type":61,"acceptedAnswer":71},"What major differences were found across regions in Nova Scotia?",{"text":72,"@type":64},"NAT receipt differed by administrative zone, with Central (73.1%) and Eastern (72.9%) higher rates than Northern (57.4%) and Western (54.2%), yielding a significant overall difference (p=0.030).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351866,1790457865,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":11,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":138,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},4398046744996,"Article  \nRegional Variations in Guideline Concordance for Women with Triple-Negative and HER2+ Breast Cancer in Nova Scotia  \nAndrea Mayo 1, Hanna Stewart 1, Tongtong Li 2,3, Cameron Penny 2, Rachel Hemsworth 1, Ashley Drohan 1,2,3, Katerina Neumann 2,3, Boris Gala-Lopez 2,3, Richard T. Spence 2,3 and Gregory Knapp 1,2,3, *  \nReceived: 26 March 2026  \nRevised: 21 May 2026  \nAccepted: 28 May 2026  \nPublished: 2 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Breast Health Research Unit, Izaak Walton Killam Health Centre, Halifax, NS B3K 6R8, Canada; [andrea.mayo@iwk.nshealth.ca](andrea.mayo@iwk.nshealth.ca) (A.M.); [hanna.stewart@iwk.nshealth.ca](hanna.stewart@iwk.nshealth.ca) (H.S.); [rachel.hemsworth@iwk.nshealth.ca](rachel.hemsworth@iwk.nshealth.ca) (R.H.); [ashley.drohan@nshealth.ca](ashley.drohan@nshealth.ca) (A.D.)  \n2 Department of Surgery, Dalhousie University, Halifax, NS B3H 2Y9, Canada; [tongtong.li@nshealth.ca](tongtong.li@nshealth.ca) (T.L.); cameron.penny@dal.ca (C.P.); [katerina.neumann@nshealth.ca](katerina.neumann@nshealth.ca) (K.N.); [boris.gala-lopez@nshealth.ca](boris.gala-lopez@nshealth.ca) (B.G.-L.); [richard.spence@nshealth.ca](richard.spence@nshealth.ca) (R.T.S.)  \n3 General Surgery Research Collaborative, Dalhousie University, Halifax, NS B3H 4R2, Canada  \n* Correspondence: [gregory.knapp@nshealth.ca](gregory.knapp@nshealth.ca)  \nSimple Summary  \nNeoadjuvant chemotherapy (NAT) is beneficial for certain aggressive subtypes of breast cancers, particularly as it allows for reduced surgical intervention and improved outcomesin these patients. Some eligible patients may not be suitable for this treatment because of co-morbidities and age, but NAT should be administered to all appropriate patients according to guidelines and it should not differ by geography. In this study, we sought to describe the amount of NAT prescribed among the breast cancer population in Nova Scotia, Canada, since the release of the Canadian NAT guidelines, and understand if this differed by geographic zone. Sixty-seven percent of the eligible Nova Scotian breast cancer patients received NAT. However, differences in the receipt of NAT by health zone were found. These results indicate geographical disparities in the receipt of guideline-concordant breast cancer care and underscore the need to better understand and remedy these disparities in healthcare.  \nAbstract  \nBackground: Systematic neoadjuvant therapy (NAT) is recommended for triple-negative (TNBC) and HER2+ breast cancers when tumor size at diagnosis is ≥2 cm. This study aimed to determine the proportion of patients in Nova Scotia with non-metastatic, incident, ≥2 cm TNBC and HER2+ breast cancer who received guideline-concordant NAT, stratified by administrative zone. Methods: This retrospective analysis utilized data from the Nova Scotia Breast Screening Program. Adult patients (18–80 years) with an incident, non-metastatic, ≥T2 breast cancer diagnosis between 2021 and 2023 were considered theoretically eligible for NAT, defined by a wait time of ≥4 months between core biopsy and surgery. Guideline-concordant care was confirmed through chart review and compared across health system administrative zones and over time. Results: Of the 291 women theoretically eligible for NAT, 67.0% received it. Significant differences in NAT receipt were observed across administrative zones (Central 73.1%, Eastern 72.9%, Northern 57.4%, Western 54.2%, p = 0.030) . Conclusions: This study identifies meaningful regional disparities in NAT receipt for TNBC and HER2+ breast cancer in Nova Scotia. Targeted strategies to improve guideline concordance are warranted and may lead to better patient outcomes.  \nKeywords: HER2; triple-negative breast cancer; neoadjuvant therapy; pathologic complete response  \n1. Introduction  \nIn Canada, ","cbCaihYJRIpwnlOQ","https://ap.wps.com/l/cbCaihYJRIpwnlOQ","pdf",833915,11,"English","# Background\n# Methods\n## Study design and population\n# Results\n# Conclusions\n# Introduction\n# Materials and Methods","[{\"question\":\"What treatment does the study focus on for eligible patients?\",\"answer\":\"The study focuses on guideline-concordant neoadjuvant systemic therapy (NAT) for non-metastatic TNBC and HER2+ breast cancers with diagnosis tumor size ≥2 cm.\"},{\"question\":\"How was eligibility for NAT determined in the analysis?\",\"answer\":\"Eligibility was based on a defined wait time of ≥4 months between core biopsy and surgery, for adult patients (18–80 years) with incident non-metastatic ≥T2 breast cancer between 2021 and 2023.\"},{\"question\":\"What major differences were found across regions in Nova Scotia?\",\"answer\":\"NAT receipt differed by administrative zone, with Central (73.1%) and Eastern (72.9%) higher rates than Northern (57.4%) and Western (54.2%), yielding a significant overall difference (p=0.030).\"}]","Regional Variations in Guideline Concordance for Women with Triple-Negative and HER2+ Breast Cancer in Nova Scotia | PDF",1790096359,28,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e2858b218d0d9799d754c3d22abd6eb.webp",983,1390,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e54f32b2533219343110ff3d034b9c8.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/caa75cf5172842f4e8cb6379b6f88bc3.webp",981,1387,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24014b9b3e259d3cad5f867a6908db3b.webp",980,1385]